Krithika Rajagopalan
Overview
Explore the profile of Krithika Rajagopalan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
97
Citations
1135
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rajagopalan K, Rashid N, Gopal D, Doshi D
Drugs Real World Outcomes
. 2025 Jan;
12(1):161.
PMID: 39762521
No abstract available.
2.
Rajagopalan K, Rashid N, Gopal D, Doshi D
Drugs Real World Outcomes
. 2024 Jun;
11(3):441-449.
PMID: 38914856
Background: Reducing falls and fractures remains an important clinical goal in managing older residents with Parkinson's disease psychosis (PDP) in long-term care/nursing home (LTC/NH) settings. Objectives: This analysis examined risk...
3.
Rajagopalan K, Rashid N, Gopal D, Doshi D
J Comp Eff Res
. 2024 Jun;
13(7):e240038.
PMID: 38850129
Real-world healthcare resource use (HCRU) burden among patients with Parkinson's disease psychosis (PDP) treated with pimavanserin (PIM) versus other atypical antipsychotics (other-AAPs) including quetiapine (QUE) in long term care (LTC)...
4.
Rajagopalan K, Rashid N, Yakkala V, Doshi D
Clinicoecon Outcomes Res
. 2024 Mar;
16:149-159.
PMID: 38495124
Background: Patients with Parkinson's disease psychosis (PDP) treated with pimavanserin (PIM) versus other atypical antipsychotics (AAPs) including quetiapine (QUE) may have health-care cost savings due to fewer skilled nursing facility-stays...
5.
Schultz B, Bullano M, Paratane D, Rajagopalan K
Transpl Infect Dis
. 2024 Jan;
26(2):e14216.
PMID: 38221739
Background: Cytomegalovirus (CMV) infections among hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT) recipients impose a significant health care resource utilization (HCRU)-related economic burden. Maribavir (MBV), a novel...
6.
Rajagopalan K, Rashid N, Doshi D
J Comp Eff Res
. 2023 Dec;
13(1):e230114.
PMID: 38099518
Risk of long-term care (LTC) admission (LTCA) associated with atypical antipsychotic (AAP) use among patients with Parkinson's disease psychosis (PDP) is a major concern. However, no comparative studies have examined...
7.
Rajagopalan K, Rashid N, Gopal D, Doshi D
Int J Geriatr Psychiatry
. 2023 Nov;
38(11):e6017.
PMID: 37936540
Background: Real-world evidence examining the incremental health care resource use (HCRU) and cost burden of incident dementia among patients with Parkinson's disease psychosis (PDP) are needed within the United States...
8.
Seyedin R, Snider J, Rajagopalan K, Wade S, Gergis U
Future Oncol
. 2023 Aug;
19(22):1535-1547.
PMID: 37578377
To investigate real-world chimeric antigen receptor (CAR) T-cell therapy treatment patterns. Relapsed/refractory large B-cell lymphoma patients who received CAR T-cell therapy were identified. Patient characteristics, setting of CAR T-cell infusion,...
9.
Rajagopalan K, Rashid N, Doshi D
J Med Econ
. 2023 Jun;
26(1):769-776.
PMID: 37272069
Background: Pimavanserin (PIM) is the only FDA approved atypical antipsychotic (AAP) for the treatment of Parkinson's Disease Psychosis (PDP) while other off-label AAPs like quetiapine (QUE) are also used. Real-world...
10.
Yunusa I, Rashid N, Seyedin R, Paratane D, Rajagopalan K
J Geriatr Psychiatry Neurol
. 2023 Jan;
36(5):417-432.
PMID: 36720473
Background: The current comparative efficacy, safety, and acceptability of atypical antipsychotics (AAPs) in treating Parkinson's Disease Psychosis (PDP) are not entirely understood. Objective: To evaluate comparative efficacy, safety, and acceptability...